Aptevo Therapeutics Inc. (APVO) Bundle
An Overview of Aptevo Therapeutics Inc. (APVO)
General Summary of Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative immuno-oncology treatments for various cancers. Founded in 2016 and headquartered in Seattle, Washington, Aptevo spun off from Emergent BioSolutions, bringing with it a pipeline of therapeutic candidates developed using proprietary ADAPTIR™ and ADAPTIR-FLEX™ technologies. The company primarily focuses on two lead clinical candidates: mipletamig (formerly APVO436) and ALG.APV-527, both designed to target specific immune pathways to enhance anti-tumor responses.
As of 2024, Aptevo offers several products, primarily in the clinical stage, with mipletamig and ALG.APV-527 being the most notable. The company reported total sales of approximately $3.1 million for the three months ended September 30, 2024, compared to $3.9 million for the same period in 2023.
Company's Financial Performance in the Latest Financial Reports
In the latest financial reports for the nine months ended September 30, 2024, Aptevo Therapeutics demonstrated a net loss of $17.8 million compared to a net loss of $11.5 million for the same period in 2023. The total revenue for the nine months was $10.5 million, down from $13.5 million in the previous year, reflecting a decrease in clinical program spending, particularly on mipletamig.
Operating expenses for the nine months ended September 30, 2024, included:
| Expense Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Research and Development | $10,498 | $13,516 |
| General and Administrative | $7,722 | $8,978 |
| Total Operating Expenses | $18,220 | $22,494 |
Additionally, for the three months ended September 30, 2024, Aptevo reported operating expenses of $5.2 million, down from $6.6 million in the same quarter of 2023. The company has successfully reduced its general and administrative expenses, which dropped to $2.1 million from $2.7 million year-over-year.
Introduction to Aptevo as a Leader in the Industry
Aptevo Therapeutics is recognized as a leader in the biotechnology sector, particularly in the immuno-oncology space. The company's innovative approach to drug development, leveraging its unique ADAPTIR technologies, positions it favorably against competitors in the rapidly evolving landscape of cancer therapeutics. As of September 30, 2024, Aptevo had cash and cash equivalents of $7.8 million and an accumulated deficit of $241.3 million, reflecting its ongoing investment in research and development.
Investors and analysts are encouraged to explore more about Aptevo's strategic initiatives and its pipeline of promising therapeutic candidates, which could significantly impact patient care and market dynamics in the oncology field.
Mission Statement of Aptevo Therapeutics Inc. (APVO)
Mission Statement of Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology candidates for treating various forms of cancer. The company's mission statement emphasizes its commitment to delivering high-quality products and services through innovation and rigorous research.
Core Component 1: Innovation
Innovation is at the heart of Aptevo's mission. The company employs advanced technologies, such as the ADAPTIR™ and ADAPTIR-FLEX™ platforms, to design precision immune modulatory drugs. For instance, as of September 2024, Aptevo initiated the Phase 1b/2 dose optimization trial for its lead candidate, mipletamig (formerly APVO436), aimed at treating acute myeloid leukemia (AML).
| Program | Current Phase | Trial Name | Target Condition |
|---|---|---|---|
| Mipletamig | Phase 1b/2 | RAINIER | Acute Myeloid Leukemia |
| ALG.APV-527 | Phase 1 | Monotherapy Trial | Solid Tumors |
Core Component 2: Quality and Safety
Aptevo is dedicated to maintaining the highest standards of quality and safety in its products. The company adheres to stringent regulatory requirements and conducts thorough clinical trials to ensure the efficacy and safety of its therapeutics. For the nine months ended September 30, 2024, Aptevo reported total research and development expenses of $10.5 million, reflecting its ongoing commitment to rigorous testing and development processes.
| Expense Type | Amount (in thousands) |
|---|---|
| Research and Development | $10,498 |
| General and Administrative | $7,722 |
Core Component 3: Patient-Centric Approach
Aptevo places significant emphasis on a patient-centric approach, aiming to address unmet medical needs through its innovative therapies. The company’s pipeline includes multiple candidates designed to provide effective treatments for patients suffering from various cancers. As of September 30, 2024, Aptevo had an accumulated deficit of $241.3 million, highlighting the investment in developing therapies that can significantly impact patient care.
| Metric | Value |
|---|---|
| Accumulated Deficit | $241.3 million |
| Net Loss (9 months ended Sept 30, 2024) | $17.8 million |
Vision Statement of Aptevo Therapeutics Inc. (APVO)
Vision Statement Overview
As of 2024, Aptevo Therapeutics Inc. (APVO) has articulated a vision statement focused on advancing the development of innovative immuno-oncology therapies, emphasizing precision and patient-centric solutions. The company aims to leverage its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms to create transformative therapies for cancer treatment.
Commitment to Innovation
Aptevo is dedicated to pioneering advancements in immunotherapy, particularly through its clinical candidates mipletamig (formerly APVO436) and ALG.APV-527, which are designed to enhance patient outcomes in oncology. The company has initiated a Phase 1b/2 trial for mipletamig, showcasing its commitment to rigorous clinical development.
Patient-Centric Approach
At the core of Aptevo's vision is a strong focus on patient needs, striving to provide therapies that not only improve survival rates but also enhance the quality of life for patients battling cancer. This approach is reflected in the design of clinical trials that prioritize patient feedback and outcomes.
Strategic Partnerships
Aptevo recognizes the importance of collaboration in achieving its vision. The company has engaged in strategic partnerships, such as the collaboration with Alligator Bioscience AB, to co-develop ALG.APV-527. These alliances are crucial for pooling resources and expertise to accelerate drug development.
Financial Outlook
As of September 30, 2024, Aptevo reported a net loss of $17.8 million, with total cash and cash equivalents amounting to $7.75 million. The company has an accumulated deficit of $241.3 million, indicating the financial challenges faced while pursuing its vision.
| Financial Metrics | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | $17.8 million | $11.5 million |
| Cash and Cash Equivalents | $7.75 million | $19.11 million |
| Accumulated Deficit | $241.3 million | $223.4 million |
Research and Development Investments
Investment in research and development is a cornerstone of Aptevo's vision. The company allocated approximately $345,000 in R&D expenses for the nine months ended September 30, 2024, reflecting its ongoing commitment to advancing its pipeline of immuno-oncology candidates.
Future Aspirations
Looking ahead, Aptevo aims to expand its portfolio of therapies and enhance its market position through continued innovation and strategic collaborations. The company is focused on overcoming current financial hurdles to realize its vision of becoming a leader in immuno-oncology therapeutics.
Core Values of Aptevo Therapeutics Inc. (APVO)
Commitment to Innovation
Aptevo Therapeutics Inc. prioritizes innovation as a core value, demonstrating its commitment through the continual development of novel therapeutics. The company's pipeline includes several promising candidates, such as mipletamig (formerly APVO436) and ALG.APV-527, developed using its proprietary ADAPTIR™ technology platform. In 2024, Aptevo initiated the Phase 1b/2 trial, "RAINIER," for mipletamig, focusing on acute myeloid leukemia (AML), highlighting its dedication to advancing cancer treatment.
As of September 30, 2024, Aptevo reported research and development expenses of $10.5 million for the nine months ended September 30, 2024, compared to $13.5 million for the same period in 2023, reflecting ongoing investment in innovation despite financial challenges.
Integrity and Accountability
Integrity and accountability are central to Aptevo's operations, ensuring that all research and clinical practices meet ethical standards. The company adheres to rigorous regulatory requirements and transparency in its financial reporting. For the nine months ended September 30, 2024, Aptevo reported a net loss of $17.8 million, with an accumulated deficit of $241.3 million, underscoring the importance of financial integrity and accountability to stakeholders.
Collaboration and Teamwork
Collaboration is vital for Aptevo, as evidenced by its partnerships with organizations like XOMA and Medexus. The collaboration with Medexus, established through a purchase agreement, allows Aptevo to receive milestone payments contingent on IXINITY sales, fostering a synergistic relationship that enhances its operational capabilities. As of September 30, 2024, Aptevo expects to receive up to $5.8 million in milestone payments from Medexus, demonstrating the tangible benefits of collaborative efforts.
Excellence in Execution
Aptevo strives for excellence in execution, focusing on the efficient management of its clinical programs. The company's operational efficiency is reflected in its research and development spending, which was $3.1 million for the three months ended September 30, 2024, down from $3.9 million in the same quarter of 2023. This reduction indicates a strategic approach to resource allocation while maintaining a commitment to advancing its clinical pipeline.
Patient-Centric Approach
Aptevo's core values include a strong patient-centric approach, emphasizing the importance of developing therapeutics that address unmet medical needs. The ongoing trials for mipletamig and ALG.APV-527 are designed to improve outcomes for patients with serious conditions like AML and solid tumors. The company reported that 60% of evaluable patients in the Phase 1 trial for ALG.APV-527 achieved stable disease, highlighting its commitment to patient welfare and treatment efficacy.
| Core Value | Description | Key Metrics |
|---|---|---|
| Commitment to Innovation | Focus on developing novel therapeutics through advanced research. | R&D Expenses: $10.5 million (2024) |
| Integrity and Accountability | Maintaining ethical practices and transparency in operations. | Net Loss: $17.8 million; Accumulated Deficit: $241.3 million |
| Collaboration and Teamwork | Fostering partnerships to enhance operational capabilities. | Expected Milestone Payments: up to $5.8 million |
| Excellence in Execution | Efficient management of clinical programs and resource allocation. | R&D Spending: $3.1 million (Q3 2024) |
| Patient-Centric Approach | Developing therapeutics aimed at improving patient outcomes. | 60% of patients achieved stable disease in ALG.APV-527 trial |
Aptevo Therapeutics Inc. (APVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Aptevo Therapeutics Inc. (APVO) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Aptevo Therapeutics Inc. (APVO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Aptevo Therapeutics Inc. (APVO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.